Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias

1 Jun 2022

Abstract excerpt

BACKGROUND: Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein-driven paediatric cancer, with MLL (KMT2A)-fusions present in most cases. Direct targeting of these driving oncoproteins represents a unique therapeutic opportunity. This rationale led us to initiate a drug screening with the aim of discovering drugs that can block...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35730653
DOI: 10.1002/ctm2.933

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemiasPMID 35730653Read ↗

Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangementsSemantic proximity Read ↗

Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological InterventionsSemantic proximity Read ↗

Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AMLSemantic proximity Read ↗

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemiaSemantic proximity Read ↗

Novel therapeutic strategies for MLL-rearranged leukemias.Semantic proximity Read ↗

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemiaSemantic proximity Read ↗

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid LeukemiaSemantic proximity Read ↗

Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic InterventionSemantic proximity Read ↗

MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integritySemantic proximity Read ↗

MLL leukemia and future treatment strategies.Semantic proximity Read ↗

Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and ClinicalSemantic proximity Read ↗

Targeting Epigenetic Programs in MLL-Rearranged LeukemiasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.